{"id":2580,"date":"2014-11-10T21:15:44","date_gmt":"2014-11-10T21:15:44","guid":{"rendered":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?p=2580"},"modified":"2014-11-10T21:15:44","modified_gmt":"2014-11-10T21:15:44","slug":"accord-bp-und-accord-lipid-studie-intensiver-heisst-nicht-immer-erfolgreicher-behandeln","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/accord-bp-und-accord-lipid-studie-intensiver-heisst-nicht-immer-erfolgreicher-behandeln\/","title":{"rendered":"ACCORD-BP- und ACCORD-Lipid-Studie: Intensiver hei\u00dft nicht immer erfolgreicher behandeln"},"content":{"rendered":"<p>AMB 2010, 44, 36 ACCORD-BP- und ACCORD-Lipid-Studie: Intensiver hei\u00dft nicht immer erfolgreicher behandeln \u00dcber die Ergebnisse der ACCORD-Studie bei Patienten mit unterschiedlich strenger Blutzuckereinstellung bei Diabetes mellitus Typ 2 (DM2) haben wir 2008 berichtet (1,\u00a02). Die Studie wurde nach einer medianen Beobachtungsdauer von 3,4 Jahren vorzeitig beendet, da die Sterblichkeit der intensiver behandelten Patienten (Ziel-HbA1c: [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AMB 2010, 44, 36 ACCORD-BP- und ACCORD-Lipid-Studie: Intensiver hei\u00dft nicht immer erfolgreicher behandeln \u00dcber die Ergebnisse der ACCORD-Studie bei Patienten mit unterschiedlich strenger Blutzuckereinstellung bei Diabetes mellitus Typ 2 (DM2) haben wir 2008 berichtet (1,\u00a02). Die Studie wurde nach einer medianen Beobachtungsdauer von 3,4 Jahren vorzeitig beendet, da die Sterblichkeit der intensiver behandelten Patienten (Ziel-HbA1c: [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[1],"tags":[1559,1557,1558,67,109,110,160,1549,78,61,111,238,362,79,112,74,60,245,113],"class_list":["post-2580","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-accord-bp","tag-accord-lipid-studie","tag-antihypertensiva","tag-apoplektischer-insult","tag-cholesterinsynthese-hemmer","tag-cse-hemmer","tag-diabetes-mellitus-typ-2","tag-fenofibrat","tag-herzinfarkt","tag-hirninfarkt","tag-hmg-coa-reduktase-hemmer","tag-hypercholesterinaemie","tag-hypertonie","tag-koronare-herzkrankheit","tag-lipidsenker","tag-myokardinfarkt","tag-schlaganfall","tag-simvastatin","tag-statine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ACCORD-BP- und ACCORD-Lipid-Studie:<\/title>\n<meta name=\"description\" content=\"ACCORD-BP- und ACCORD-Lipid-Studie: Intensiver hei\u00dft nicht immer erfolgreicher behandeln - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken --&gt;\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/accord-bp-und-accord-lipid-studie-intensiver-heisst-nicht-immer-erfolgreicher-behandeln\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ACCORD-BP- und ACCORD-Lipid-Studie:\" \/>\n<meta property=\"og:description\" content=\"ACCORD-BP- und ACCORD-Lipid-Studie: Intensiver hei\u00dft nicht immer erfolgreicher behandeln - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken --&gt;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/accord-bp-und-accord-lipid-studie-intensiver-heisst-nicht-immer-erfolgreicher-behandeln\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"2014-11-10T21:15:44+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg\" \/>\n<meta name=\"author\" content=\"henk-amb\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"henk-amb\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"6\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/accord-bp-und-accord-lipid-studie-intensiver-heisst-nicht-immer-erfolgreicher-behandeln\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/accord-bp-und-accord-lipid-studie-intensiver-heisst-nicht-immer-erfolgreicher-behandeln\\\/\"},\"author\":{\"name\":\"henk-amb\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\"},\"headline\":\"ACCORD-BP- und ACCORD-Lipid-Studie: Intensiver hei\u00dft nicht immer erfolgreicher behandeln\",\"datePublished\":\"2014-11-10T21:15:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/accord-bp-und-accord-lipid-studie-intensiver-heisst-nicht-immer-erfolgreicher-behandeln\\\/\"},\"wordCount\":1301,\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/accord-bp-und-accord-lipid-studie-intensiver-heisst-nicht-immer-erfolgreicher-behandeln\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/_images\\\/link.jpeg\",\"keywords\":[\"ACCORD-BP\",\"ACCORD-Lipid-Studie\",\"Antihypertensiva\",\"Apoplektischer Insult\",\"Cholesterinsynthese-Hemmer\",\"CSE-Hemmer\",\"Diabetes mellitus Typ 2\",\"Fenofibrat\",\"Herzinfarkt\",\"Hirninfarkt\",\"HMG-CoA-Reduktase-Hemmer\",\"Hypercholesterin\u00e4mie\",\"Hypertonie\",\"Koronare Herzkrankheit\",\"Lipidsenker\",\"Myokardinfarkt\",\"Schlaganfall\",\"Simvastatin\",\"Statine\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/accord-bp-und-accord-lipid-studie-intensiver-heisst-nicht-immer-erfolgreicher-behandeln\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/accord-bp-und-accord-lipid-studie-intensiver-heisst-nicht-immer-erfolgreicher-behandeln\\\/\",\"name\":\"ACCORD-BP- und ACCORD-Lipid-Studie:\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/accord-bp-und-accord-lipid-studie-intensiver-heisst-nicht-immer-erfolgreicher-behandeln\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/accord-bp-und-accord-lipid-studie-intensiver-heisst-nicht-immer-erfolgreicher-behandeln\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/_images\\\/link.jpeg\",\"datePublished\":\"2014-11-10T21:15:44+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\"},\"description\":\"ACCORD-BP- und ACCORD-Lipid-Studie: Intensiver hei\u00dft nicht immer erfolgreicher behandeln - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/accord-bp-und-accord-lipid-studie-intensiver-heisst-nicht-immer-erfolgreicher-behandeln\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/accord-bp-und-accord-lipid-studie-intensiver-heisst-nicht-immer-erfolgreicher-behandeln\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/accord-bp-und-accord-lipid-studie-intensiver-heisst-nicht-immer-erfolgreicher-behandeln\\\/#primaryimage\",\"url\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/_images\\\/link.jpeg\",\"contentUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/_images\\\/link.jpeg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/accord-bp-und-accord-lipid-studie-intensiver-heisst-nicht-immer-erfolgreicher-behandeln\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ACCORD-BP- und ACCORD-Lipid-Studie: Intensiver hei\u00dft nicht immer erfolgreicher behandeln\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\",\"name\":\"henk-amb\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"caption\":\"henk-amb\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ACCORD-BP- und ACCORD-Lipid-Studie:","description":"ACCORD-BP- und ACCORD-Lipid-Studie: Intensiver hei\u00dft nicht immer erfolgreicher behandeln - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/accord-bp-und-accord-lipid-studie-intensiver-heisst-nicht-immer-erfolgreicher-behandeln\/","og_locale":"de_DE","og_type":"article","og_title":"ACCORD-BP- und ACCORD-Lipid-Studie:","og_description":"ACCORD-BP- und ACCORD-Lipid-Studie: Intensiver hei\u00dft nicht immer erfolgreicher behandeln - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/accord-bp-und-accord-lipid-studie-intensiver-heisst-nicht-immer-erfolgreicher-behandeln\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"2014-11-10T21:15:44+00:00","og_image":[{"url":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg","type":"","width":"","height":""}],"author":"henk-amb","twitter_misc":{"Verfasst von":"henk-amb","Gesch\u00e4tzte Lesezeit":"6\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/accord-bp-und-accord-lipid-studie-intensiver-heisst-nicht-immer-erfolgreicher-behandeln\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/accord-bp-und-accord-lipid-studie-intensiver-heisst-nicht-immer-erfolgreicher-behandeln\/"},"author":{"name":"henk-amb","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937"},"headline":"ACCORD-BP- und ACCORD-Lipid-Studie: Intensiver hei\u00dft nicht immer erfolgreicher behandeln","datePublished":"2014-11-10T21:15:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/accord-bp-und-accord-lipid-studie-intensiver-heisst-nicht-immer-erfolgreicher-behandeln\/"},"wordCount":1301,"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/accord-bp-und-accord-lipid-studie-intensiver-heisst-nicht-immer-erfolgreicher-behandeln\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg","keywords":["ACCORD-BP","ACCORD-Lipid-Studie","Antihypertensiva","Apoplektischer Insult","Cholesterinsynthese-Hemmer","CSE-Hemmer","Diabetes mellitus Typ 2","Fenofibrat","Herzinfarkt","Hirninfarkt","HMG-CoA-Reduktase-Hemmer","Hypercholesterin\u00e4mie","Hypertonie","Koronare Herzkrankheit","Lipidsenker","Myokardinfarkt","Schlaganfall","Simvastatin","Statine"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/accord-bp-und-accord-lipid-studie-intensiver-heisst-nicht-immer-erfolgreicher-behandeln\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/accord-bp-und-accord-lipid-studie-intensiver-heisst-nicht-immer-erfolgreicher-behandeln\/","name":"ACCORD-BP- und ACCORD-Lipid-Studie:","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/accord-bp-und-accord-lipid-studie-intensiver-heisst-nicht-immer-erfolgreicher-behandeln\/#primaryimage"},"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/accord-bp-und-accord-lipid-studie-intensiver-heisst-nicht-immer-erfolgreicher-behandeln\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg","datePublished":"2014-11-10T21:15:44+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937"},"description":"ACCORD-BP- und ACCORD-Lipid-Studie: Intensiver hei\u00dft nicht immer erfolgreicher behandeln - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/accord-bp-und-accord-lipid-studie-intensiver-heisst-nicht-immer-erfolgreicher-behandeln\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/accord-bp-und-accord-lipid-studie-intensiver-heisst-nicht-immer-erfolgreicher-behandeln\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/accord-bp-und-accord-lipid-studie-intensiver-heisst-nicht-immer-erfolgreicher-behandeln\/#primaryimage","url":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg","contentUrl":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/accord-bp-und-accord-lipid-studie-intensiver-heisst-nicht-immer-erfolgreicher-behandeln\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"ACCORD-BP- und ACCORD-Lipid-Studie: Intensiver hei\u00dft nicht immer erfolgreicher behandeln"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937","name":"henk-amb","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","caption":"henk-amb"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/2580","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/comments?post=2580"}],"version-history":[{"count":3,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/2580\/revisions"}],"predecessor-version":[{"id":2667,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/2580\/revisions\/2667"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/media?parent=2580"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/categories?post=2580"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/tags?post=2580"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}